Deguelin is known to suppress the growth of cancer cells; however, its anti-metastatic effects have not been studied so far in any cancer model. In the present study, we aimed to evaluate the anti-metastatic potential of deguelin in vivo and in tumor growth factor-b1 (TGFb1)-stimulated cells. Our results demonstrate that tumor growth, peritoneal dissemination and liver/lung metastasis of orthotopically implanted PanC-1-luc cells were significantly reduced in deguelin-treated mice along with the induction of apoptosis. Furthermore, deguelin-treated tumors showed increased epithelial signature such as increased expression of E-Cadherin and cytokeratin-18 and decreased expression of Snail. Similar observations were made when PanC-1, COLO-357 and L3.6pl cells were treated in vitro with deguelin. Moreover, E-cadherin was transcriptionally upregulated and accumulated in the membrane fraction of deguelin-treated cells, as indicated by increased interaction of E-Cadherin with b-catenin. TGFb1-induced downregulation of E-Cadherin and upregulation of Snail were abrogated by deguelin treatment. In addition, deguelin inhibited TGFb1-induced Smad3 phosphorylation and Smad4 nuclear translocation in PanC-1 cells. Furthermore, when TGFb1-induced nuclear factor kappa B (NFkB) activation was inhibited, TGFb1-induced Snail upregulation or E-Cadherin downregulation was blocked. Deguelin also significantly downregulated the constitutive phosphorylation and DNA binding of NFkB in a dosedependent manner. Interestingly, overexpression of either NFkB or Snail completely abrogated deguelin-mediated epithelial-tomesenchymal transition (EMT) inhibition, whereas overexpression of NFkB but not Snail rescued cells from deguelin-induced apoptosis. Hence, deguelin targets NFkB to induce reversal of EMT and apoptosis but downstream effectors might be different for both processes. Taken together, our results suggest that deguelin suppresses both pancreatic tumor growth and metastasis by inducing apoptosis and inhibiting EMT. 1 Most of the patients with pancreatic cancer develop metastasis and die because of the debilitating metabolic effects of their unrestrained growth.
INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. 1 Most of the patients with pancreatic cancer develop metastasis and die because of the debilitating metabolic effects of their unrestrained growth. 2 Several wellknown factors such as late detection and resistance to chemoand radiotherapy contribute to poor survival rate. Pancreatic cancer commonly metastasize to the abdominal cavity, lymph nodes and liver. 3 Emerging evidences suggest that epithelial-to-mesenchymal transition (EMT) is a key process in tumor cell invasiveness and metastasis. Previous reports have shown a close association between pancreatic cancer progression and EMT. 4 In fact several pancreatic cancer cell lines and surgically resected pancreatic tumors have shown strong EMT characteristics. [4] [5] [6] Interestingly, increase in fibronectin or vimentin and decrease in E-Cadherin expression in tumors correlates with poor survival. 5 A recent report has shown that 43% (13/30) of primary pancreatic tumors and 53% (8/15) of metastatic tumors have increased levels of N-Cadherin, indicating the potential role of EMT in pancreatic cancer metastasis. 6 Tumor growth factor-b1 (TGFb1) can induce and maintain EMT during embryogenesis and cancer progression. 7 It induces EMT by canonical Smad signaling and/or non-canonical TGFb/TAK1/IKK/ NFkB signaling, but both the pathways merges on Snail to repress E-Cadherin expression. 8 The most important suppressors of E-Cadherin are Snail-related zinc-finger transcription factors such as Snail, Slug and SIP-1/ZEB. 9 Interestingly, Snail-knockout animals die at gastrulation stages and show defects in EMT, indicating the role of Snail in EMT induction. 10 Recently, nuclear factor kappa B (NFkB) was identified as a central mediator of EMT by regulating Snail expression. 11, 12 Huber et al. 11 have shown that the activation of NFkB promoted the transition to a mesenchymal phenotype even in the absence of TGFb. Moreover, inhibition of NFkB in metastatic cells resulted in reversal of EMT, suggesting that the IKK-2/IkBa/NFkB pathway is required for the induction and maintenance of EMT in epithelial cancer cells.
various cancer models such as breast, colon and lung cancer. [14] [15] [16] Intravenous injection of deguelin showed a mean residence time of 6 .98 h and terminal half-life (t1/2) of 9.26 h. About 58% and 14% of the deguelin was eliminated via feces and urine, respectively, within 5 days of intragastric administration of deguelin. 17 Previous reports have shown that deguelin inhibits the survival of various cancer cells by targeting the key survival pathways such as AKT, Wnt, NFkB and cell cycle proteins. [14] [15] [16] 18, 19 However, the antimetastatic potentials of deguelin have not been investigated in any cancer model. The present study was designed to elucidate the role of deguelin on EMT and metastasis in pancreatic cancer.
RESULTS
Deguelin inhibits primary tumor growth and spontaneous in vivo metastasis of pancreatic tumors Previous reports have shown that deguelin inhibits the growth of cancer cells. 16, 20, 21 In the present study, we evaluated whether deguelin could inhibit the metastasis of pancreatic cancer along with primary tumor growth. To determine the anti-metastasis potential of deguelin in vivo, mice that were orthopically implanted with PanC-1-luc cells were treated with 5 mg/kg deguelin (1:1 corn oil:dimethylsulphoxide, daily, intraperitoneal (i.p.)), and tumor growth and metastasis were monitored using IVIS Bio Imaging Station. Our results show that deguelin substantially reduced the primary tumor growth by 73% (7.6 Â 10 As liver is the preferential site of metastasis for most of the pancreatic tumors, we imaged the luminescence in liver. Luciferin was injected 10 min before killing the mice, livers were excised and luminescence was measured by the imaging system. As shown in Figure 2e , liver from deguelintreated mice showed no or modest luminescence, whereas control mice livers demonstrated strong luminescence indicating that deguelin significantly inhibits the metastasis of pancreatic tumors to liver.
Deguelin inhibits EMT in vivo
As the primary objective of the present study was to evaluate the anti-metastatic potential of deguelin, we focused further studies on metastasis. Inhibition of pancreatic tumor metastasis and migration by deguelin in vivo prompted us to examine whether the anti-metastatic effect of deguelin was due to the inhibition of EMT. Interestingly, our immunofluorescence studies show that As Snail is considered to be the main transcriptional repressor of E-Cadherin, we monitored the expression of Snail in response to deguelin treatment. Interestingly, our results show that Snail expression was significantly reduced in all the three cells lines in a dose-and time-dependent manner (Figures 5a and b) . However, Snail and E-Cadherin were not altered by deguelin treatment in To differentiate between the cytotoxic effects of deguelin with that of reversal of EMT, we used gemcitabine, which is a known chemotherapeutic drug used in clinics against pancreatic cancer. Our results show that gemcitabine treatment decreased the survival of PanC-1 and COLO-357 cells similar to that of deguelin ( Figure 5c and Figure 4a ). However, in contrast to deguelin, gemcitabine treatment failed to induce E-Cadherin expression or reduce vimentin expression in pancreatic cancer cells (Figure 5c ). In fact, previous reports have shown that gemcitabine-and tamoxifen-treated cells acquire EMT phenotype. [22] [23] [24] Hence, deguelin is unique as it not only suppresses pancreatic tumor growth but also suppress metastasis by inhibiting EMT.
Deguelin transcriptionally increases membrane-bound E-Cadherin and downregulates cytosolic E-Cadherin Next, we wanted to see whether deguelin induces E-Cadherin expression transcriptionally or by altering the post-translational degradation. Our reverse transcription (RT)-PCR analysis shows that E-Cadherin was transcriptionally upregulated in deguelintreated PanC-1 (Figure 5d) . Surprisingly, the increase in E-Cadherin protein expression by deguelin treatment in the whole-cell lysates did not correlated exactly as mRNA levels (Figures 5b and d ). E-Cadherin is known to mis-localize in various portions of the cell such as cytosol and nucleus, hence, we wanted to see whether deguelin alters the localization of E-Cadherin. Interestingly, our results show that membrane-bound E-Cadherin was significantly increased whereas, cytosolic E-Cadherin was downregulated. However, nuclear E-Cadherin was unaltered in deguelin-treated PanC-1 cells (Figure 5d, right panel) . Furthermore, b-catenin interaction was increased in deguelin-treated cell lysates that was immunoprecipitated with E-Cadherin (Figure 4e ), indicating that E-Cadherin is accumulated in membrane fraction. Immunofluorescence studies further confirmed the localization of E-Cadherin and its repressor Snail (Figure 5e , right panel).
Deguelin suppresses TGFb1-induced EMT Family of TGFb growth factors can initiate and maintain EMT in variety of biological systems. 25 Hence, we wanted to see whether deguelin would inhibit TGFb1-induced EMT in pancreatic cancer cells. As shown in Figure 6a Deguelin downregulates Snail expression by inhibiting TGFb1 non-canonical NFkB pathway Interestingly, deguelin treatment increased E-Cadherin expression in L3.6pl, BxPC-3 and MIA PaCa-2 cells (data not shown), which do not have intact functional TGFb1 signaling due to mutation in Smad4 (L3.6pl and BxPC-3) or lack of TGFb receptors (MIA PaCa-2).
26 TGFb1 is also known to induce EMT in various cancer types by Smad-independent pathways such as NFkB. 27 On the basis of these facts, we hypothesized that deguelin could also target noncanonical TGFb pathway to inhibit EMT by modulating NFkB. To evaluate the role of NFkB in TGFb1-induced EMT, NFkB was silenced using SiRNA in PanC-1 and COLO-357 cells. As expected, our results show that NFkB-silenced PanC-1 or COLO-357 cells were completely insensitive to TGFb1-induced EMT (Figure 7a) . Furthermore, we observed maximum NFkB phosphorylation (Ser-536) and nuclear accumulation after 2 h of TGFb1 treatment in PanC-1 cells (Figure 7a, right panel) . As NFkB was a prerequisite for TGFb1-induced EMT, we next wanted to evaluate the effect of deguelin on NFkB signaling pathway. Our results show that deguelin significantly inhibit the constitutive IkB (Ser-32/34) and NFkB (Ser-536) phosphorylation in pancreatic cells without affecting the protein levels (Figure 7b) . Similarly, TGFb1-induced phosphorylation of IkB (Ser-32/34) and NFkB (Ser-536) were also drastically reduced by deguelin treatment (Figure 7b (Figures 8a and b) . However, when Snail overexpressing cells were treated with deguelin, EMT inhibition mediated by deguelin was almost completely blocked in PanC-1 and COLO-357 cells (Figures 8a and b) , indicating the critical role of Snail in deguelinmediated EMT inhibition. Interestingly, NFkB was not altered significantly by Snail overexpression, indicating that NFkB may not be regulated by Snail in our model (Figures 8a and b) .
Similarly, when NFkB was overexpressed in PanC-1 or COLO-357 cells, E-Cadherin expression was reduced. On the other hand, expression of N-Cadherin and vimentin was increased in both the cells (Figures 8c and d) , indicating the role of NFkB in EMT. Interestingly, NFkB overexpression also resulted in the increased expression of Snail, providing direct evidence on the role of NFkB in inducing EMT through Snail (Figures 8c and d) . Nonetheless, when NFkB overexpressing PanC-1 or COLO-357 cells were treated with deguelin, E-Cadherin induction or vimentin and Snail downregulation was abolished (Figures 8c and d) . Interestingly, Snail overexpression did not protected the cells from deguelininduced apoptosis, whereas NFkB overexpression significantly rescued the cells from deguelin-induced apoptosis (Figures 8a-d) .
DISCUSSION
In the present study, we investigated the role of deguelin on pancreatic tumor growth and metastasis in vivo and in vitro. Our results show that deguelin significantly inhibits the peritoneal dissemination and liver metastasis of orthotopically implanted PanC-1-luc cells in nude mice along with induction of apoptosis. Furthermore, deguelin significantly downregulated the mesenchymal markers and increased the expression of epithelial markers in vivo and in vitro, indicating that deguelin targets EMT to inhibit metastasis of pancreatic tumors along with primary tumor growth. In the present study, we established that deguelin targets TGFb1 canonical Smad signaling and non-canonical NFkB signaling pathway to downregulate Snail expression leading to the induction of E-Cadherin. Deguelin also suppresses primary pancreatic tumor growth by targeting NFkB.
As pancreatic tumors have high tendency to metastasize to peritoneal organs such as liver, spleen and intestinal mesentery nodules, peritoneal dissemination and liver metastasis were used as parameters to measure pancreatic tumor metastasis. As compared with control tumors, deguelin-treated tumors reduced peritoneal dissemination and blocked metastasis to liver. Interestingly, control tumors were more diffused and less compact as compared with deguelin-treated tumors. On the basis of these observations, we hypothesized that deguelin target tight junction proteins, which are necessary to bind epithelial cells to each other, to prevent tumor diffusion (metastasis). E-Cadherin is a tight junction protein that is differentially expressed in compact and diffused tumors, 28, 29 and has a critical role in tumor metastasis. 30 ,31 E-Cadherin expression was significantly increased by deguelin treatment; whereas mesenchymal markers were decreased in vitro and in vivo confirming that deguelin inhibits EMT in pancreatic cancer. It appears that upregulation of E-Cadherin by deguelin in our model was due to the inhibition of Snail, an endogenous repressor of E-Cadherin. Surprisingly, the increase in E-Cadherin mRNA by deguelin did not exactly correlated with the protein expression of E-Cadherin in PanC-1 cells. Furthermore, the extent of Snail downregulation also did not correlated with E-Cadherin upregulation as expected.
One plausible reason could be that concomitant with Snail downregulation, deguelin might be activating other E-Cadherin repressors such as Slug and Twist. However, both the repressors Slug and Twist were downregulated by deguelin treatment (data not shown). Another possibility that exists is the localization of E-Cadherin. Primarily, E-Cadherin is expressed as transmembrane protein that interacts with b-catenin to maintain cell-cell adhesion. 32 Salahshor et al. 33 have reported that 24% pancreatic tumors show abnormal localization of E-Cadherin in the cytosol and nucleus. Thus, we hypothesized that overall increase in E-Cadherin expression by deguelin treatment was due to the increase in membrane-bound E-Cadherin. In agreement with our hypothesis, deguelin significantly downregulated E-Cadherin expression in cytosolic fraction whereas increased its expression in the membrane fraction of the cells. Our hypothesis was also strengthened by the observation that E-Cadherin and b-catenin interactions were increased in deguelin-treated PanC-1 cells, confirming that more E-Cadherin was accumulated in membrane fraction.
EMT can be induced or regulated by various growth factors such as TGFb1, FGF, HGF, PDGF, Wnt and Notch. 7 TGFb is known to induce EMT by Smad-dependent (canonical) and Smad-independent (non-canonical) pathways. 27 It is possible that deguelin specifically targets R-Smads to inhibit TGFb1 signaling, as Smad3 activation (Ser-423/425) was significantly suppressed by deguelin in TGFb1primed cells, without affecting the protein levels of Smad4. TGFb1 modulate NFkB activity in certain epithelial cells, 8, 34 and NFkB is essential for TGFb1-induced EMT in certain cancers such as breast cancer. 11 Interestingly, when NFkB was silenced in PanC-1 and COLO-357 cells and treated with TGFb1, TGFb1-induced Snail induction and E-Cadherin downregulation was completely prevented. NFkB overexpression induced Snail expression and downregulated E-Cadherin in PanC-1 and COLO-357 cells. On the other hand, TGFb1 treatment resulted in the phosphorylation of IkB (Ser-32) and NFkB (Ser-536). Taken together, these observations indicate that NFkB-Snail pathway is indispensable for TGFb1-induced EMT in pancreatic cancer cells. Interestingly, deguelin significantly inhibited both constitutive and TGFb1-induced activation of IkB (Ser-32/34) and NFkB (Ser-536) in PanC-1 cells and orthotopically implanted tumors. Furthermore, overexpression of either NFkB or Snail completely abrogated EMT inhibition by deguelin, indicating that deguelin targets NFkB-Snail pathway to inhibit EMT in pancreatic cancer. Interestingly, ectopic expression of NFkB induced Snail expression but Snail overexpression did not induced NFkB expression, indicating that NFkB acts upstream and regulates Snail in our model.
There could be two possible mechanisms by which deguelin inhibit NFkB activation in pancreatic cancer cells: (a) TGFb1 induce NFkB nuclear localization by TGFb-activated kinase (TAK1)-dependent IkB phosphorylation, 8 and (b) RKIP-mediated inhibition of NFkB activation by interacting with various upstream kinases such as NIK and TAK1. [35] [36] [37] Deguelin significantly inhibited TAK1-induced phosphorylation of IkB (Ser-32) in TGFb-treated cells. Inhibition of IkB phosphorylation by deguelin lead to stabilization of NFkB-IkB interaction thus prevent nuclear translocation of NFkB and obligatory TGFb1-induced Snail induction. As, deguelin treatment significantly induced RKIP expression, it could lead to the inhibition of NFkB activation.
To evaluate whether deguelin-induced reversal of EMT and apoptosis induction were through a common pathway, induction of apoptosis (Cl. Caspase-3 and Cl. PARP) was evaluated in deguelin-treated NFkB or Snail overexpressing PanC-1 and COLO-357 cells. Interestingly, deguelin-induced apoptosis was completely blocked in NFkB overexpressing cells but not in Snail overexpressing cells. Nevertheless, EMT reversal by deguelin was significantly blocked in both NFkB and Snail overexpressing cells. These results suggest that upstream regulator, such as NFkB, has significant role in both deguelin-induced reversal of EMT and apoptosis process, however, the downstream effectors are different. For example, Snail overexpression failed to protect the cells from deguelin-induced apoptosis but significantly prevented EMT reversal, suggesting that Snail or EMT plays no role in the apoptosis induction through deguelin in our model. A schematic diagram of deguelin targets is presented in Figure 9 .
In conclusion, deguelin suppresses both pancreatic tumor growth and metastasis by inducing apoptosis and inhibiting EMT.
MATERIALS AND METHODS

Chemicals and antibodies
Deguelin and TGF-b1 were purchased from Sigma Chemicals (Sigma, St Louis, MO, USA). All the antibodies were procured from Cell Signaling Technology Inc. (Danvers, MA, USA). . Human pancreatic ductal epithelial cells (HPDE-6) were generously provided by Dr Ming-Sound Tsao (University of Toronto, Toronto, Ontario, Canada). All the cell lines were maintained in DMEM medium except HPDE-6, which were cultured in keratinocyte-SFM medium as described by us earlier. 38 Orthotopic implantation of PanC-1 luciferase cells
PanC-1
Snail
PanC-1-luc cells were orthotopically implanted in the pancreas of nude mice, as described by us earlier. 39 All the experiments involving animals were approved by the Institutional Animal Care and Use Committee. Twenty 4-to 6-week-old female athymic nude mice (Charles River, Wilmington, MA, USA) were kept on an antioxidant-free AIN-76A diet (TestDiet, Richmond, IN, USA) during the experiment. The mice were used in each group to get better statistical difference. Sample size was calculated using the software developed by DuPont and Plummer. The following parameters were used to calculate the sample size: a (0.1), d (0.5), s (0.5) and power (0.9). 40 Animals were anesthetized by KetamineXylazine-Acepromazine mixture and a small left abdominal flank incision was made. Around 1 Â 10 6 exponentially growing PanC-1-luc cells suspended in 20 ml PBS were injected into the subcapsular region of the pancreas. The peritoneum and skin incisions were closed sequentially with absorbable suture. Animals were imaged on the next day of surgery for basal luminescence using IVIS Bio Luminescent System equipped with Living Image software (Caliper LifeSciences, Hopkinton, MA, USA). After 7 days, mice were randomly separated into two groups with 10 mice in each group. Mice in the experimental group received 5 mg/kg deguelin (daily, i.p., 37 days), whereas the control mice received vehicle alone. Dose of the deguelin was selected based on previously published literature. [41] [42] [43] Tumor luminescence and animal weight was measured twice a week for 6 weeks. At the end of the experiment (day 45), mice were killed; tumors and pancreas were excised from each mouse weighed and snap-frozen for western blot and immunofluorescence analysis. Tumor migration from the site of injection was measured by Living Image software (Caliper LifeSciences).
Cytotoxicity, wound healing, transwell and RT-PCR analysis PanC-1, COLO-357 and L3.6pl cells were treated with various concentrations of deguelin, and cytotoxicity, wound healing and transwell assays were performed as described by us earlier. 44, 45 Total RNA was extracted from control and deguelin-treated cells, and RT-PCR analysis was performed as described by us earlier 45 using E-Cadherin sense and antisense primers 5 0 -CGCCCTATGATTCTCTGCTCG-3 0 and 5 0 -TCGTCCTCGCC GCCTCCGTA-3 0 , respectively.
TGF-b1 treatment
Cells were plated in a six-well plate at a density of 0.3 Â 10 6 cells/well and left overnight. Next day, cells were serum-starved overnight and media was replaced with fresh media containing 10 ng/ml TGF-b1. After 48 h of incubation, various concentrations of deguelin were added to TGF-b1-treated cells and coincubated for additional 24 h. Cells were collected and subjected to either western blot analysis or immunostained and observed under microscope.
NFkB transcriptional activity and DNA binding (electrophoretic mobility shift assay) PanC-1 or COLO-357 cells were treated with deguelin (10 mM) for 24 h ,and nuclear and cytosolic fractions were collected. NFkB DNA-binding activity and transcriptional activity was measured as described by us earlier. 46 
Transient transfections
PanC-1 or COLO-357 cells were transiently reverse transfected with either NFkB or Snail overexpressing plasmids using FuGene 6 (Roche Diagnostics Corporation, Indianapolis, IN, USA) transfection reagent, according to the manufacturer's instructions. Briefly, either 2 mg of NFkB-plasmid-DNA or 1.5 mg of Snail-plasmid-DNA for PanC-1 and 3 mg of NFkB-plasmid-DNA or 2 mg of Snail-plasmid-DNA for COLO-357 was diluted separately in Opti-MEM media to which FuGene transfection reagent was added in a ratio of 1:3 (w:v) and incubated at room temperature for 1 h in a six-well plate. After incubation, Panc-1 or COLO-357 cells were trypsinized and around 0.3 Â 10 6 cells were added separately to DNA-FuGene complexes formed in the six-well plates and incubated for another 5 h. Medium was replaced with fresh media and incubated for additional 48 h. Transfected cells were either treated with 0.1% dimethylsulphoxide or deguelin (10 mM) for 24 h. Cells were collected and subjected to western blot analysis.
Western blot analysis
Treated and control cells were collected and lysed in lysis buffer containing protease and phosphatase inhibitors by incubating on ice for 20 min The protein concentration was estimated by Bradford reagent (BioRad, Hercules, CA, USA). Forty microgram of protein was resolved on 10-12% SDS-polyacrylamide gel electrophoresis and transferred on to polyvinylidene fluoride membrane for western blot analysis as described by us previously. 44, 47 Statistical analysis All the statistical analysis was performed using Prism 5.0 software (Graph Pad software Inc., San Diego, CA, USA). Results were expressed as mean ± s.d. of at least three independent experiments. Data were analyzed by Student's t-test or one way ANOVA followed by Bonferroni's post-hoc analysis for multiple comparisons. Differences were considered statistically significant at Po0.05.
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